Go Together, Go Far: China Biotech Cannot Go Global Without Regional Collaboration
Facing an unprecedented downturn, Chinese biopharma companies cannot be self-reliant to go global, investors say during a Hong Kong Biotech Summit.
You may also be interested in...
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
The Southeast Asian island nation could emerge a winner as China and Hong Kong continue to show few signs of easing their strict COVID policies and companies look to diversify their global supply chains.
After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.